- CA$36.01m
- CA$45.42m
- CA$16.79m
- 20
- 36
- 65
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.75% | ||
| Return on Equity | n/a | ||
| Operating Margin | -49.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.17 | 1.57 | 3.27 | 4.05 | 16.79 | n/a | n/a | 169.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients’ needs and enhances the patient's journey.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 25th, 2016
- Public Since
- July 18th, 2019
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 90,033,790
- Address
- 480 UNIVERSITY AVENUE, SUITE 1502, TORONTO, M5G 1V2
- Web
- https://avicanna.com/
- Phone
- +1 6472435283
- Auditors
- Kingston Ross Pasnak LLP
Upcoming Events for AVCN
Avicanna Inc Annual Shareholders Meeting
Q2 2024 Avicanna Inc Earnings Release
Similar to AVCN
AEterna Zentaris
Toronto Stock Exchange
Antibe Therapeutics(Pre-Merger)
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
FAQ
What is the Avicanna share price?
As of Today at 19:03 UTC, shares in Avicanna are trading at CA$0.40. This share price information is delayed by 15 minutes.
How has the Avicanna share price performed this year?
Shares in Avicanna last closed at CA$0.40 and the price had moved by +1.27% over the past 365 days. In terms of relative price strength the Avicanna share price has underperformed the Toronto Stock Exchange 300 Composite Index by -4.84% over the past year.
What are the analyst and broker recommendations for Avicanna?
The overall consensus recommendation for Avicanna is Sell. You can view the full broker recommendation list by unlocking its StockReport.
What is the Avicanna dividend yield?
Avicanna does not currently pay a dividend.
Does Avicanna pay a dividend?
Avicanna does not currently pay a dividend.
When does Avicanna next pay dividends?
Avicanna does not currently pay a dividend.
How do I buy Avicanna shares?
To buy shares in Avicanna you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avicanna?
As of the previous close price of CA$0.40, shares in Avicanna had a market capitalisation of CA$36.01m.
Where are Avicanna shares listed?
Here are the trading details for Avicanna:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: AVCN
What kind of share is Avicanna?
Based on an overall assessment of its quality, value and momentum Avicanna is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avicanna share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Avicanna share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avicanna. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -32.38%.
As of the last closing price of CA$0.40, shares in Avicanna were trading +0.95% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avicanna PE Ratio?
The Avicanna PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avicanna?
We do not have data on Avicanna's directors